StockData
Fennec Pharmaceuticals Inc. logo

Fennec Pharmaceuticals Inc. (FENC) shareholders

FENCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3088% above fair value
$13.58+0.82 (+6.43%)

Close on Nov 17, 2026Market cap $476.21MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
46.5%
16M of 35M shares
Institutional holders
105
25 new, 8 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
0 buys · 17 sales
Net sold $10.03M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Rosalind Advisors, Inc.
Joint filing with Salamon Steven A J (9.40%), Aharon Gil (9.40%) and 1 more
3,321,3339.60%13G (passive) amendmentJun 30, 2026
Kam Lawrence
Joint filing with Sonic Fund II, L.P. (7.60%), Sonic GP LLC (7.60%)
2,799,9598.20%13G (passive) amendmentDec 31, 2025
Southpoint Master Fund, LP
Joint filing with Southpoint Capital Advisors LP (8.00%), Southpoint Capital Advisors LLC (8.00%) and 3 more
2,744,7418.00%13G (passive) amendmentDec 31, 2025
Orin Hirschman
Joint filing with AIGH Capital Management LLC (7.10%)
2,499,4217.10%13G (passive) amendmentSep 30, 2026
Solas Capital Management, LLC
Joint filing with Frederick Tucker Golden (7.20%)
2,482,1987.20%13G (passive) amendmentMar 31, 2026
Frederick Tucker Golden
Joint filing with Solas Capital Management, LLC (5.40%)
1,889,3665.40%13G (passive) amendmentJun 30, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of FENCValueChange% of portfolio
Rosalind Advisors, Inc.3,188,0019.09%$34.27M+279,80012.73%
AIGH Capital Management LLC2,486,0387.09%$26.72M+504,5371.68%
Solas Capital Management, LLC1,889,3665.39%$20.31M−592,83210.88%
BlackRock, Inc.1,727,0694.93%$18.57M+358,8930.00%
AWM Investment Company, Inc.1,160,2963.31%$12.47M+440,1611.08%
Vanguard Capital Management LLC839,3062.39%$9.02M−57,8380.00%
Prospect Capital Advisors, LLC497,8001.42%$5.35MNew2.43%
State Street Corp426,0041.21%$4.58M+66,9490.00%
Geode Capital Management, LLC402,5661.15%$4.33M+30,8280.00%
Jane Street Group, LLC233,8770.67%$2.51MNew0.00%
Potomac Capital Management, Inc.224,4000.64%$2.41M–1.65%
Morgan Stanley221,9200.63%$2.39M+10,8120.00%
Vanguard Portfolio Management LLC199,9980.57%$2.15M+31,5250.00%
Northern Trust Corp167,9220.48%$1.81M+15,7990.00%
Marshall Wace, Llp138,7580.40%$1.49MNew0.00%
Renaissance Technologies LLC134,2000.38%$1.44MNew0.00%
Nuveen, LLC131,4820.37%$1.41M+70,5340.00%
Trexquant Investment LP119,1220.34%$1.28M+67,2530.01%
CenterBook Partners LP118,5820.34%$1.27MNew0.06%
Lion Point Capital, LP112,4340.32%$1.21M–5.78%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202610516M46.5%25 / 4418 / 84M4M
Q1 20269016M46.2%16 / 3818 / 203M1M
Q4 20259616M44.3%20 / 2624 / 84M2M
Q3 20258414M39.6%11 / 2724 / 51M1M
Q2 20257814M38.8%16 / 2524 / 61M1M
Q1 20256813M38.2%9 / 2120 / 31M1M
Q4 20246416M45.8%13 / 2514 / 122M1M
Q3 20246315M42.6%8 / 2615 / 82M0M
Q2 20246414M41.0%17 / 2512 / 171M1M
Q1 20246515M41.8%14 / 2517 / 52M2M
Q4 20235615M43.1%7 / 2214 / 62M1M
Q3 20235514M40.8%3 / 1716 / 40M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

75 funds held FENC in Q2 2026, 70% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of FENCValue% of fundAs of
Vanguard Total Stock Market Index Fund815,1922.32%$8.76M0.00%Jun 30, 2026
iShares Russell 2000 ETF750,3692.14%$8.07M0.01%Jun 30, 2026
Fidelity Small Cap Index Fund316,4710.90%$3.03M0.01%Jul 31, 2026
iShares Russell 2000 Growth ETF266,7150.76%$2.87M0.02%Jun 30, 2026
Vanguard Russell 2000 Index Fund149,1560.43%$1.48M0.01%May 31, 2026
Ultra-Small Company Fund108,0050.31%$1.16M1.18%Jun 30, 2026
iShares Micro-Cap ETF97,1150.28%$1.04M0.07%Jun 30, 2026
College Retirement Equities Fund - Total Global Stock Account85,1240.24%$915.08K0.00%Jun 30, 2026
Schwab Small-Cap Index Fund70,5040.20%$674.72K0.01%Jul 31, 2026
Master Small Cap Index Series50,4810.14%$542.67K0.01%Jun 30, 2026
Nuveen Small Cap Blend Index Fund33,8130.10%$323.59K0.01%Jul 31, 2026
EQ/2000 Managed Volatility Portfolio33,3800.10%$358.84K0.01%Jun 30, 2026
Fidelity Small Cap Growth Index Fund27,2110.08%$292.52K0.02%Jun 30, 2026
Fidelity Nasdaq Composite Index Fund19,5870.06%$194.50K0.00%May 31, 2026
Invesco Russell 2000 Dynamic Multifactor ETF18,2280.05%$181.00K0.06%May 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Jeffrey S. HackmanChief Executive Officer, Director70,8440.20%Nov 2, 2026
Christiana Marie CioffiChief Strategy Officer28,9020.08%Nov 2, 2026
Pierre Sargis SayadChief Medical Officer13,7010.04%Nov 2, 2026
Terry L. EvansChief Commercial Officer24,1810.07%Nov 2, 2026
Robert AndradeCHIEF FINANCIAL OFFICER248,5580.71%Nov 2, 2026
Marco Maria BrugheraDirector0–Nov 16, 2026
Jodi A. CookDirector––Jun 10, 2026
Khalid IslamDirector133,3330.38%Jun 10, 2026
Chris A. RallisDirector63,0770.18%Jun 10, 2026
Rosty Raykov–124,4110.35%Sep 1, 2026
Capital Advisors LLC Southpoint10% owner3,744,74110.68%Dec 29, 2025
Southpoint GP, LP10% owner4,077,21411.63%Dec 29, 2025
Southpoint GP, LLC10% owner3,764,08210.73%Dec 29, 2025
Capital Advisors LP Southpoint10% owner2,744,7417.83%Dec 29, 2025
John Smith Clark II10% owner41,504,000118.36%Dec 29, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Marco Maria Brughera
Director
Nov 13, 2026Sale(10b5-1 plan)−20,000$12.00$240.00K0
Marco Maria Brughera
Director
Nov 13, 2026Option exercise+20,000$2.11$42.20K20,000
Christiana Marie Cioffi
Chief Strategy Officer
Oct 31, 2026Award+156––28,902
Pierre Sargis Sayad
Chief Medical Officer
Oct 31, 2026Award+168––13,701
Terry L. Evans
Chief Commercial Officer
Oct 31, 2026Award+168––24,181
Jeffrey S. Hackman
Chief Executive Officer, Director
Oct 31, 2026Award+1,159––70,844
Robert Andrade
CHIEF FINANCIAL OFFICER
Oct 31, 2026Award+1,703––248,558
Christiana Marie Cioffi
Chief Strategy Officer
Oct 12, 2026Award+3,946$5.53$21.82K28,746
Pierre Sargis Sayad
Chief Medical Officer
Oct 12, 2026Award+3,846$5.53$21.27K13,533
Terry L. Evans
Chief Commercial Officer
Oct 12, 2026Award+2,326$5.53$12.86K24,013
Jeffrey S. Hackman
Chief Executive Officer, Director
Oct 12, 2026Award+2,224$5.53$12.30K69,685
Robert Andrade
CHIEF FINANCIAL OFFICER
Oct 12, 2026Award+3,846$5.53$21.27K246,855
Christiana Marie Cioffi
Chief Strategy Officer
Sep 30, 2026Award+156––24,800
Pierre Sargis Sayad
Chief Medical Officer
Sep 30, 2026Award+168––9,687
Terry L. Evans
Chief Commercial Officer
Sep 30, 2026Award+168––21,687
Jeffrey S. Hackman
Chief Executive Officer, Director
Sep 30, 2026Award+1,159––67,461
Robert Andrade
CHIEF FINANCIAL OFFICER
Sep 30, 2026Award+1,703––243,009
Marco Maria Brughera
Director
Sep 15, 2026Sale(10b5-1 plan)−15,545$10.29$159.96K0
Marco Maria Brughera
Director
Sep 15, 2026Option exercise+15,545$2.11$32.80K15,545
Rosty Raykov
–
Sep 1, 2026Sale(10b5-1 plan)−10,000$12.11$121.10K124,411
Rosty Raykov
–
Aug 31, 2026Award+2,778––134,411
Jeffrey S. Hackman
Chief Executive Officer, Director
Aug 31, 2026Award+1,159––66,302
Terry L. Evans
Chief Commercial Officer
Aug 31, 2026Award+168––21,519
Pierre Sargis Sayad
Chief Medical Officer
Aug 31, 2026Sale−12,000$12.18$146.16K9,519
Pierre Sargis Sayad
Chief Medical Officer
Aug 31, 2026Award+168––21,519
Robert Andrade
CHIEF FINANCIAL OFFICER
Aug 31, 2026Award+1,703––241,306
Christiana Marie Cioffi
Chief Strategy Officer
Aug 31, 2026Award+156––24,644
Robert Andrade
CHIEF FINANCIAL OFFICER
Aug 28, 2026Option exercise+21,928$5.10$111.83K239,603
Robert Andrade
CHIEF FINANCIAL OFFICER
Aug 27, 2026Sale(10b5-1 plan)−75,000$11.78$883.50K217,675
Rosty Raykov
–
Aug 3, 2026Sale(10b5-1 plan)−10,000$9.58$95.80K131,633
Pierre Sargis Sayad
Chief Medical Officer
Jul 31, 2026Award+168––21,351
Rosty Raykov
–
Jul 31, 2026Award+2,778––141,633
Jeffrey S. Hackman
Chief Executive Officer, Director
Jul 31, 2026Award+1,159––65,143
Robert Andrade
CHIEF FINANCIAL OFFICER
Jul 31, 2026Award+1,703––292,675
Christiana Marie Cioffi
Chief Strategy Officer
Jul 31, 2026Award+156––24,488
Terry L. Evans
Chief Commercial Officer
Jul 31, 2026Award+168––21,351
Rosty Raykov
–
Jul 1, 2026Sale(10b5-1 plan)−9,599$10.41$99.93K138,855
Rosty Raykov
–
Jul 1, 2026Option exercise+15,597$2.45$38.21K148,454
Rosty Raykov
–
Jul 1, 2026Award+2,778––132,857
Pierre Sargis Sayad
Chief Medical Officer
Jun 30, 2026Award+168––21,183
Robert Andrade
CHIEF FINANCIAL OFFICER
Jun 30, 2026Award+1,703––290,972
Terry L. Evans
Chief Commercial Officer
Jun 30, 2026Award+168––21,183
Christiana Marie Cioffi
Chief Strategy Officer
Jun 30, 2026Award+156––24,332
Jeffrey S. Hackman
Chief Executive Officer, Director
Jun 30, 2026Award+1,159––63,984
Rosty Raykov
Director
Jun 1, 2026Option exercise+15,597$2.45$38.21K139,826
Rosty Raykov
Director
Jun 1, 2026Sale(10b5-1 plan)−9,747$9.62$93.77K130,079
Rosty Raykov
Director
May 31, 2026Award+2,778––124,229
Robert Andrade
CHIEF FINANCIAL OFFICER
May 31, 2026Award+1,703––289,269
Christiana Marie Cioffi
Chief Strategy Officer
May 31, 2026Award+156––24,176
Terry L. Evans
Chief Commercial Officer
May 31, 2026Award+168––21,015
Jeffrey S. Hackman
Chief Executive Officer, Director
May 31, 2026Award+1,159––62,825
Pierre Sargis Sayad
Chief Medical Officer
May 31, 2026Award+168––21,015
Chris A. Rallis
Director
May 11, 2026Sale(10b5-1 plan)−8,346$7.04$58.76K63,077
Chris A. Rallis
Director
May 11, 2026Option exercise+14,344$2.44$35.00K71,423
Rosty Raykov
Director
May 1, 2026Option exercise+15,598$2.45$38.22K132,232
Rosty Raykov
Director
May 1, 2026Sale(10b5-1 plan)−10,781$6.47$69.75K121,451
Pierre Sargis Sayad
Chief Medical Officer
Apr 30, 2026Option exercise+168––20,847
Jeffrey S. Hackman
Chief Executive Officer, Director
Apr 30, 2026Option exercise+1,159––61,666
Terry L. Evans
Chief Commercial Officer
Apr 30, 2026Option exercise+168––20,847
Rosty Raykov
Director
Apr 30, 2026Option exercise+2,778––116,634

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
1.30%
0M shares short
Days to cover
3.9
At 0M shares a day
Change since last report
-6.8%
From 0M shares
Short volume, 20 days
36.8%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Fennec Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 12,034 shares on Sep 16, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Marco Maria Brughera
Director
Sep 15, 202615,545$160.07KSep 15, 2026Stock Option Exercise
Rostislav Raykov
Former Director
Sep 1, 202610,000$121.18KSep 1, 2026Restricted Stock
Pierre Sargis Sayad
Officer
Aug 31, 202612,000$146.17KAug 31, 2026Performance Shares
Robert Andrade
Officer
Aug 27, 202675,000$883.90KAug 27, 2026Exercised Shares
Rostislav Raykov
Former Director
Aug 3, 202610,000$95.84KAug 3, 2026Restricted Stock
Rostislav Raykov
Director
Jul 1, 20269,599$99.99KJul 1, 2026Stock Option Exercise
Rostislav Raykov
Director
Jun 1, 20269,747$93.81KJun 1, 2026Stock Option Exercise
Chris A. Rallis
Director
May 11, 20268,346$58.83KMay 11, 2026Stock Option Exercise
Rostislav Raykov
Director
May 1, 202610,781$69.76KMay 1, 2026Stock Option Exercise
Rostislav Raykov
Director
Apr 1, 202610,946$69.07KApr 1, 2026Stock Option Exercise
Rostislav Raykov
Director
Mar 2, 202610,079$84.35KMar 2, 2026Stock Option Exercise
Rostislav Raykov
Director
Feb 2, 202610,349$80.34KFeb 2, 2026Stock Option Exercise
Rostislav Raykov
Director
Jan 2, 202610,312$78.47KJan 2, 2026Stock Option Exercise
Rostislav Raykov
Director
Dec 5, 202510,000$75.44KDec 5, 2025Restricted Stock
Rostislav Raykov
Director
Nov 5, 202510,000$81.08KNov 5, 2025Restricted Stock

See a number that looks wrong?